MK-0448, a Specific Kv1.5 Inhibitor: Safety, Pharmacokinetics, and Pharmacodynamic Electrophysiology in Experimental Animal Models and Humans

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Circulation: Arrhythmia and Electrophysiology

• Publication date

  2012-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCEP.111.969782PMID 23060423
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacological Cardioversion of Atrial Fibrillation

  2012cited by this paper
• Pathophysiological mechanisms of atrial fibrillation: a translational appraisal.

  2011cited by this paper
• Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling.

  2009cited by this paper
• New Pharmacological Strategies for the Treatment of Atrial Fibrillation

  2009cited by this paper
• Atrial Antifibrillatory Effects of Structurally Distinct IKur Blockers 3-[(Dimethylamino)methyl]-6-methoxy-2-methyl-4-phenylisoquinolin-1(2H)-one and 2-Phenyl-1,1-dipyridin-3-yl-2-pyrrolidin-1-yl-ethanol in Dogs with Underlying Heart Failure

  2008cited by this paper
• Can inhibition of IKur promote atrial fibrillation?

  2008cited by this paper
• New Drugs Targeting the Cardiac Ultra-Rapid Delayed-Rectifier Current (IKur): Rationale, Pharmacology and Evidence for Potential Therapeutic Value

  2008cited by this paper
• Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches.

  2008cited by this paper
• In Vivo Cardiac Electrophysiologic and Antiarrhythmic Effects of an Isoquinoline IKur Blocker, ISQ-1, in Rat, Dog, and Nonhuman Primate

  2007cited by this paper
• Innovative approaches to anti-arrhythmic drug therapy

  2006cited by this paper
• Shortening of fibrillatory cycle length in the pulmonary vein during vagal excitation.

  2006cited by this paper
• ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Commit

  2006cited by this paper
• Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation.

  2006influential reference
• Guidelines for the Management of Patients With Atrial Fibrillation

  2006cited by this paper
• Gender Differences in Electrophysiologic Effects of Mental Stress and Autonomic Tone Inhibition: A Study in Healthy Individuals

  2005cited by this paper
• Gender Differences in Electrophysiologic Effects of Mental Stress and Autonomic Tone Inhibition:

  2005cited by this paper
• Antiarrhythmic drugs

  2004cited by this paper
• Role of I Kur in Controlling Action Potential Shape and Contractility in the Human Atrium Influence of Chronic Atrial Fibrillation

  2004cited by this paper
• Relationships Between Sinus Rhythm, Treatment, and Survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study

  2004cited by this paper
• Role of IKur in Controlling Action Potential Shape and Contractility in the Human Atrium: Influence of Chronic Atrial Fibrillation

  2004cited by this paper
• Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.

  2004cited by this paper
• Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.

  2003cited by this paper
• A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation

  2003cited by this paper
• Temporal Relations of Atrial Fibrillation and Congestive Heart Failure and Their Joint Influence on Mortality The Framingham Heart Study

  2003cited by this paper
• A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study.

  2002cited by this paper
• A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

  2002cited by this paper
• A population-based study of mortality among patients with atrial fibrillation or flutter.

  2002cited by this paper
• Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.

  2000cited by this paper
• Antiarrhythmic drugs

  1995cited by this paper
• Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

  1993cited by this paper
• Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the Cardiac Arrhythmia Suppression Trial (CAST).

  1993cited by this paper
• Respiration‐synchronous fluctuations in stroke volume, heart rate and arterial pressure in humans.

  1993cited by this paper
• Autonomic control of cardiac chronotropic function in man as a function of age: assessment by power spectral analysis of heart rate variability.

  1991cited by this paper
• Accuracy of assessment of cardiac vagal tone by heart rate variability in normal subjects.

  1991cited by this paper

• K+ channel blockade limits AF and suppresses phase 3 EADs by slowing repolarization in an electromechanical cell computational model

  2026cites this paper
• SNAP25-dependent membrane trafficking of the Kv1.5 channel regulates the onset of atrial fibrillation

  2025cites this paper
• Atrial hiPSC-CM as a pharmacological model to evaluate anti-AF drugs: Some lessons from IKur.

  2024cites this paper
• Inhibition of the voltage-gated potassium channel Kv1.5 by hydrogen sulfide attenuates remodeling through S-nitrosylation-mediated signaling

  2023cites this paper
• Research on atrial fibrillation mechanisms and prediction of therapeutic prospects: focus on the autonomic nervous system upstream pathways

  2023cites this paper
• Common Structural Pattern for Flecainide Binding in Atrial-Selective Kv1.5 and Nav1.5 Channels: A Computational Approach

  2022cites this paper
• Small Conductance Ca2 +-Activated K+ (SK) Channel mRNA Expression in Human Atrial and Ventricular Tissue: Comparison Between Donor, Atrial Fibrillation and Heart Failure Tissue

  2021cites this paper
• Investigational Anti–Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020?

  2020cites this paper
• Populations of in silico myocytes and tissues reveal synergy of multiatrial‐predominant K+‐current block in atrial fibrillation

  2020cites this paper
• Antiarrhythmic Drugs

  2019cites this paper
• Ion channel drug discovery and modern medicine

  2019cites this paper
• Atria-selective antiarrhythmic drugs in need of alliance partners.

  2019cites this paper
• Mechanisms and Drug Development in Atrial Fibrillation

  2018cites this paper
• Suppression of Kv1.5 protects against endothelial apoptosis induced by palmitate and in type 2 diabetes mice

  2017cites this paper
• Cardiac potassium channels: physiological insights for targeted therapy.

  2017cites this paper
• Atrial-selective K+ channel blockers: potential antiarrhythmic drugs in atrial fibrillation?

  2017cites this paper
• Investigational antiarrhythmic agents: promising drugs in early clinical development

  2017cites this paper
• Atrial fibrillation: Therapeutic potential of atrial K+ channel blockers.

  2017cites this paper
• Synergistic Anti-arrhythmic Effects in Human Atria with Combined Use of Sodium Blockers and Acacetin

  2017influential citation
• Cardiac Potassium Channels: Physiological Insights for Targeted Therapy

  2017cites this paper
• Rate-Dependent Role of IKur in Human Atrial Repolarization and Atrial Fibrillation Maintenance.

  2017cites this paper
• Discovery of MK-1832, a Kv1.5 inhibitor with improved selectivity and pharmacokinetics.

  2017cites this paper
• Anti-arrhythmic strategies for atrial fibrillation: The role of computational modeling in discovery, development, and optimization.

  2016cites this paper
• The positive frequency-dependent electrophysiological effects of the IKur inhibitor XEN-D0103 are desirable for the treatment of atrial fibrillation

  2016cites this paper
• Kv1.5 Inhibitors for Treatment of Atrial Fibrillation: A Tradeoff between Selectivity and Non-selectivity.

  2016cites this paper
• Effects of Potassium Channel Blockers

  2016cites this paper
• Mechanism of Proarrhythmic Effects of Potassium Channel Blockers.

  2016cites this paper
• Atrial-Selective Potassium Channel Blockers.

  2016cites this paper
• The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.

  2016cites this paper
• First clinical trial of specific IKACh blocker shows no reduction in atrial fibrillation burden in patients with paroxysmal atrial fibrillation: pacemaker assessment of BMS 914392 in patients with paroxysmal atrial fibrillation.

  2016cites this paper
• Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans.

  2015influential citation
• Inhibition of IKr potentiates development of atrial-selective INa block leading to effective suppression of atrial fibrillation.

  2015cites this paper
• Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy

  2015influential citation
• Novel K+ Channel Targets in Atrial Fibrillation Drug Development—Where Are We?

  2015influential citation
• Cardiac ion channels

  2015cites this paper
• Chapter Eight - Current Approaches to the Treatment of Atrial Fibrillation

  2014cites this paper
• Atrial Fibrillation Therapy Now and in the Future: Drugs, Biologicals, and Ablation

  2014cites this paper
• Pharmacology of voltage-gated potassium channel Kv1.5--impact on cardiac excitability.

  2014cites this paper
• Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillation

  2014cites this paper
• [New developments in the antiarrhythmic therapy of atrial fibrillation].

  2014cites this paper
• Stimulation of glucose uptake in murine soleus muscle and adipocytes by 5-(4-phenoxybutoxy)psoralen (PAP-1) may be mediated by Kv1.5 rather than Kv1.3

  2014cites this paper
• Lactam sulfonamides as potent inhibitors of the Kv1.5 potassium ion channel.

  2014cites this paper
• Neue Entwicklungen in der antiarrhythmischen Therapie des Vorhofflimmerns

  2014cites this paper
• Design, synthesis and evaluation of phenethylaminoheterocycles as K(v)1.5 inhibitors.

  2014cites this paper
• Cardiac potassium channel subtypes: new roles in repolarization and arrhythmia.

  2014cites this paper
• Triazolo and imidazo dihydropyrazolopyrimidine potassium channel antagonists.

  2013cites this paper
• Atrial selectivity of antiarrhythmic drugs

  2013cites this paper
• Electrophysiological Characterization and Antiarrhythmic Efficacy of the Mixed Potassium Channel-Blocking Antiarrhythmic Agent AZ13395438 In Vitro and In Vivo

  2013cites this paper
• Rhythm control of atrial fibrillation in heart failure.

  2013cites this paper